Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2019
November 12, 2019 06:30 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
November 07, 2019 08:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Host Analyst and Investor Day on November 18, 2019 in New York City
October 07, 2019 07:00 ET
|
Surface Oncology, Inc.
Keynote speaker: E. John Wherry, Ph.D., director, Penn Institute for Immunology, University of Pennsylvania, and Co-Director of the Parker Institute for Cancer Immunotherapy at PennPresentations from...
Surface Oncology to Present at the Baird 2019 Global Healthcare Conference
September 03, 2019 16:05 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
September 03, 2019 07:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), today announced Ramy Ibrahim, M.D., will join the company’s board of directors. Dr. Ibrahim is a medical...
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019
August 07, 2019 06:05 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Participate in 40th Annual Goldman Sachs Global Healthcare Conference
June 07, 2019 12:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019
May 24, 2019 06:00 ET
|
Surface Oncology, Inc.
Presentation provides updated in vivo efficacy data supporting adenosine reduction for cancer treatmentData also support anti-CD39 candidate’s capability to invoke both innate and adaptive immune...
Surface Oncology to Present at Two Upcoming Healthcare Conferences
May 15, 2019 16:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2019
May 09, 2019 07:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...